title: Clinical characteristics and treatment results of pediatric osteosarcoma: the role of high dose chemotherapy with autologous stem cell transplantation.
abstract: OBJECTIVE
  In this study, we investigated the clinical characteristics and treatment results of osteosarcoma during the past 7 years, and evaluated the role of high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT).
  
  
  METHODS
  We retrospectively analyzed the clinical data of patients who were diagnosed as osteosarcoma at our center from January, 2000 to December, 2007.
  
  
  RESULTS
  The 5-year overall survival and event-free survival of the patients were 72.6% and 55.9%, respectively. Seventeen (41.5%) patients showed disease progression during treatment or relapse after the end of treatment. The patients who had metastasis at diagnosis or who had a lower grade of necrosis after neoadjuvant chemotherapy showed decreased overall and event-free survival. Four patients received ASCT after HDCT, and 3 of them are alive without disease.
  
  
  CONCLUSIONS
  The patients who relapsed or had refractory osteosarcoma or who had metastasis at diagnosis or a lower grade of necrosis after neoadjuvant chemotherapy showed poor prognosis. HDCT with ASCT could be an alternative treatment option for these patients.
authors.affiliation: Division of Hematology/Oncology, Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Lee
authors.forename: Hyery
authors.initials: H
authors.lastname: Kim
authors.forename: Hyoung Jin
authors.initials: HJ
authors.lastname: Kang
authors.forename: Han-Soo
authors.initials: HS
authors.lastname: Kim
authors.forename: Sung-Hye
authors.initials: SH
authors.lastname: Park
authors.forename: In-One
authors.initials: IO
authors.lastname: Kim
authors.forename: Hyo Seop
authors.initials: HS
authors.lastname: Ahn
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Shin
references.citation: Bone Marrow Transplant. 2004 Jul;34(1):37-41
references.pmid: 15170176
references.citation: Cancer Treat Rev. 2006 Oct;32(6):423-36
references.pmid: 16860938
references.citation: J Clin Oncol. 1991 Oct;9(10):1766-75
references.pmid: 1717666
references.citation: J Clin Oncol. 2002 Feb 1;20(3):776-90
references.pmid: 11821461
references.citation: J Clin Oncol. 1998 Jul;16(7):2452-8
references.pmid: 9667263
references.citation: J Clin Oncol. 1983 Jul;1(7):428-31
references.pmid: 6607977
references.citation: Cancer. 1993 Dec 1;72(11):3227-38
references.pmid: 8242546
references.citation: Cancer. 1992 Feb 1;69(3):698-708
references.pmid: 1730120
references.citation: Cancer Treat Res. 1993;62:85-92
references.pmid: 8096763
references.citation: Cancer. 1990 Jun 1;65(11):2539-53
references.pmid: 2337871
references.citation: Curr Opin Oncol. 2007 Jul;19(4):341-6
references.pmid: 17545797
references.citation: J Bone Joint Surg Am. 1970 Apr;52(3):411-23
references.pmid: 5269156
references.citation: J Clin Oncol. 2002 Apr 15;20(8):2150-6
references.pmid: 11956277